Litoxetine | CAS#86811-09-8 | serotonin uptake inhibitor

MedKoo Cat#: 599035 | Name: Litoxetine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Litoxetine is a serotonin uptake inhibitor.

Chemical Structure

Litoxetine

CAS#86811-09-8

Theoretical Analysis

MedKoo Cat#: 599035

Name: Litoxetine

CAS#: 86811-09-8

Chemical Formula: C16H19NO

Exact Mass: 241.1467

Molecular Weight: 241.33

Elemental Analysis: C, 79.63; H, 7.94; N, 5.80; O, 6.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Litoxetine; Litoxetina; Litoxetinum;

IUPAC/Chemical Name

4-(naphthalen-2-ylmethoxy)piperidine

InChi Key

MJJDYOLPMGIWND-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H19NO/c1-2-4-15-11-13(5-6-14(15)3-1)12-18-16-7-9-17-10-8-16/h1-6,11,16-17H,7-10,12H2

SMILES Code

C1(OCC2=CC=C3C=CC=CC3=C2)CCNCC1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 241.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lucchelli A, Santagostino-Barbone MG, Masoero E, Baiardi P, Tonini M. Influence of fluoxetine and litoxetine on 5-HT4 receptor-mediated relaxation in the rat isolated oesophagus. Fundam Clin Pharmacol. 1999;13(3):330-6. PubMed PMID: 10392309. 2: Fairweather DB, Patat A, Rosenzweig P, Curson VH, Dunmore C, Dubruc C, Hindmarch I. The psychomotor and cognitive effects of litoxetine in young and middle aged volunteers. Br J Clin Pharmacol. 1995 Aug;40(2):119-25. PubMed PMID: 8562293; PubMed Central PMCID: PMC1365170. 3: Patat A, Trocherie S, Thébault JJ, Rosenzweig P, Dubruc C, Bianchetti G, Morselli PL, Court LA. EEG profile of litoxetine after single and repeated administration in healthy volunteers. Br J Clin Pharmacol. 1994 Feb;37(2):157-63. PubMed PMID: 8186061; PubMed Central PMCID: PMC1364592. 4: Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ. Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol. 1993 Mar 2;232(2-3):139-45. PubMed PMID: 8385615. 5: Perrault G, Morel E, Zivkovic B, Sanger DJ. Activity of litoxetine and other serotonin uptake inhibitors in the tail suspension test in mice. Pharmacol Biochem Behav. 1992 May;42(1):45-7. PubMed PMID: 1528946. 6: Lucchelli A, Santagostino-Barbone MG, Barbieri A, Candura SM, Tonini M. The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT3 and 5-HT4 receptors. Br J Pharmacol. 1995 Mar;114(5):1017-25. PubMed PMID: 7780635; PubMed Central PMCID: PMC1510312. 7: Andrews M, Brown A, Chiva JY, Fradet D, Gordon D, Lansdell M, MacKenny M. Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. doi: 10.1016/j.bmcl.2009.02.054. Epub 2009 Feb 20. PubMed PMID: 19282174. 8: Andrews M, Brown A, Chiva JY, Fradet D, Gordon D, Lansdell M, MacKenny M. Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. doi: 10.1016/j.bmcl.2009.08.066. Epub 2009 Aug 21. PubMed PMID: 19740658. 9: Graham D, Langer SZ. Advances in sodium-ion coupled biogenic amine transporters. Life Sci. 1992;51(9):631-45. Review. PubMed PMID: 1501510. 10: Angel I, Taranger MA, Claustre Y, Scatton B, Langer SZ. Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro. Life Sci. 1988;43(8):651-8. PubMed PMID: 3261828. 11: Brocco M, Dekeyne A, Veiga S, Girardon S, Millan MJ. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav. 2002 Apr;71(4):667-80. PubMed PMID: 11888558. 12: Agnel M, Esnaud H, Langer SZ, Graham D. Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. Biochem Pharmacol. 1996 May 3;51(9):1145-51. PubMed PMID: 8645336. 13: Danilov DS. [Multimodal serotonergic antidepressants]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(9):103-111. doi: 10.17116/jnevro201711791103-111. Russian. PubMed PMID: 29053130.